Papilledema
Papilledema refers specifically to bilateral optic disc swelling caused by elevated intracranial pressure (ICP). It is a critical neurologic sign rather than a diagnosis, signaling the presence of an underlying condition that requires urgent evaluation. The term should be distinguished from optic disc edema of other causes (optic neuritis, ischemic optic neuropathy, infiltrative optic neuropathy) and from pseudopapilledema, which mimics the appearance without true elevation of ICP. Idiopathic intracranial hypertension (IIH) is the most common cause of papilledema in young adults, while mass lesions, cerebral venous sinus thrombosis (CVST), and meningitis must be excluded in all patients. The management of papilledema is directed at the underlying cause, with the primary goal of preserving vision.
Bottom Line
- Papilledema = elevated ICP: Bilateral disc swelling from raised intracranial pressure; always warrants urgent neurologic evaluation including brain imaging before lumbar puncture
- Frisen grading: A standardized 6-grade scale (0–5) for classifying papilledema severity based on fundoscopic features; higher grades correlate with greater visual field loss
- Symptoms of raised ICP: Transient visual obscurations (seconds-long vision graying with positional changes), headache (often worse with Valsalva), pulsatile tinnitus, and horizontal diplopia (CN6 palsy — a false localizing sign)
- Workup sequence: Neuroimaging (MRI brain + MRV) → lumbar puncture with opening pressure (if no mass lesion) → visual field testing + OCT for monitoring
- IIH diagnosis: Modified Dandy criteria — symptoms/signs of raised ICP, normal brain parenchyma on imaging, elevated opening pressure (>25 cm H2O), normal CSF composition, no alternative cause
- Pseudopapilledema: Optic disc drusen is the most common mimic; distinguished by B-scan ultrasound (calcification), enhanced depth imaging OCT, and fundus autofluorescence
- Vision-threatening papilledema: Fulminant IIH with rapid visual decline requires emergency intervention (serial lumbar punctures, optic nerve sheath fenestration, or CSF shunting)
Pathophysiology
Papilledema results from the transmission of elevated intracranial pressure to the optic nerve via the subarachnoid space that surrounds the nerve within its dural sheath. The mechanism involves:
- CSF pressure transmission: The optic nerve is surrounded by a meningeal sheath continuous with the intracranial meninges; elevated ICP increases pressure within the perioptic subarachnoid space
- Axoplasmic flow stasis: Elevated pressure at the lamina cribrosa impedes both orthograde and retrograde axoplasmic transport in retinal ganglion cell axons, leading to axonal swelling at the disc
- Venous congestion: Compression of small venules within the optic nerve head contributes to disc edema and peripapillary hemorrhages
- Bilateral involvement: Because the pressure is transmitted equally to both optic nerves, papilledema is characteristically bilateral, though it may be asymmetric (more prominent on the side with more axons or a smaller scleral canal)
- Visual loss mechanism: Chronic axonal compression leads to progressive retinal ganglion cell loss; visual field defects begin peripherally (enlarged blind spot, nasal step) and progress centrally in advanced cases
Frisen Grading Scale
The Frisen scale is the standard classification system for papilledema severity. It grades disc edema from 0 (normal) to 5 (severe) based on specific fundoscopic features visible on ophthalmoscopy.
| Grade | Description | Key Features |
|---|---|---|
| Grade 0 | Normal | Normal optic disc; spontaneous venous pulsations may be present (absent in ~20% of normal individuals) |
| Grade 1 | Very early | C-shaped halo of disc edema (nasal, superior, inferior margins); disruption of normal radial nerve fiber layer (NFL) striations; temporal disc margin is spared; subtle blurring of nasal disc border |
| Grade 2 | Early | Complete circumferential halo of disc edema (now includes temporal margin); concentric or radial peripapillary NFL folds (Paton lines); no obscuration of major vessels |
| Grade 3 | Moderate | Disc borders are completely obscured; increased disc diameter; peripapillary halo; obscuration of one or more major vessel segments on the disc |
| Grade 4 | Marked | Elevation of the entire disc head; obscuration of all vessels on the disc surface; peripapillary halo may be compressed; possible cotton-wool spots and hemorrhages |
| Grade 5 | Severe | Dome-shaped protrusion of the disc; total obscuration of vessels on and leaving the disc; peripapillary hemorrhages and cotton-wool spots common; may see venous congestion and retinal folds extending toward macula |
Frisen Grade and Visual Prognosis
- Grades 1–2: Visual fields may be normal or show only enlarged blind spot; visual acuity is typically preserved; these grades indicate early papilledema that may stabilize or improve with treatment
- Grade 3: Visual field loss becomes detectable (nasal step, arcuate defects, inferonasal constriction); acuity may still be normal
- Grades 4–5: Significant visual field constriction; increasing risk of irreversible visual loss from chronic axonal damage; acuity may decline
- Chronic papilledema → optic atrophy: Prolonged papilledema leads to "secondary optic atrophy" — the disc becomes pale with gliotic changes, visual field loss becomes permanent, and the disc edema resolves (deceptively improved disc appearance despite worsening visual function)
- Key point: Visual acuity is a LATE finding in papilledema; visual field testing is the critical measure for detecting early visual deterioration
Clinical Manifestations of Raised ICP
Visual Symptoms
- Transient visual obscurations (TVOs): Brief episodes (seconds) of graying, blurring, or complete blackout of vision, often triggered by positional changes (standing, bending, Valsalva); present in 70% of IIH patients. TVOs reflect transient ischemia of the swollen optic nerve head and do not necessarily indicate imminent permanent visual loss.
- Enlarged blind spot: The earliest and most common visual field defect; caused by peripapillary edema displacing the peripapillary retina. May be asymptomatic and only detected on formal perimetry.
- Progressive visual field loss: Inferonasal constriction, arcuate defects, nasal steps — similar to glaucomatous field loss; indicates chronic axonal damage
- Decreased visual acuity: A late finding; occurs when central macular fibers are damaged from chronic papilledema or acute ischemia in fulminant cases
Non-Visual Symptoms
- Headache: Present in >90% of IIH patients; typically diffuse, worse in the morning, exacerbated by Valsalva, coughing, or bending; may be migrainous in quality. Some patients have minimal or no headache.
- Pulsatile tinnitus: A whooshing sound synchronous with heartbeat, reported in 50–65% of IIH patients; caused by turbulent flow in the transverse/sigmoid sinuses from elevated ICP
- CN6 palsy: Horizontal diplopia from unilateral or bilateral abducens palsy — a false localizing sign of raised ICP (CN6 has a long intracranial course and is compressed against the petrous apex). Present in 10–30% of IIH patients.
- Neck stiffness and radicular pain: Occasionally reported; may reflect meningeal distension from elevated CSF pressure
Causes of Papilledema
| Category | Specific Causes | Key Features / Notes |
|---|---|---|
| Idiopathic intracranial hypertension (IIH) | Most common cause in young, obese women | Diagnosis of exclusion; modified Dandy criteria; associated with obesity (BMI >30), recent weight gain, female sex, childbearing age |
| Cerebral venous sinus thrombosis (CVST) | Superior sagittal, transverse, sigmoid sinus thrombosis | Must be excluded in ALL patients presenting with papilledema; MRV is mandatory; risk factors include oral contraceptives, pregnancy, thrombophilia, infection |
| Mass lesions | Brain tumor, abscess, subdural hematoma, hydrocephalus | Contrast-enhanced MRI brain is the first imaging study; posterior fossa tumors are especially associated with papilledema from obstructive hydrocephalus |
| Meningitis / encephalitis | Infectious (TB, cryptococcal, bacterial), carcinomatous, sarcoid | CSF analysis is diagnostic; cryptococcal meningitis in immunosuppressed patients frequently causes severe papilledema |
| Medications | Tetracyclines (minocycline, doxycycline), vitamin A / retinoids, lithium, growth hormone, corticosteroid withdrawal | Medication history is essential; tetracyclines are the most commonly implicated |
| Medical conditions | Severe hypertension (malignant), renal failure, severe OSA, Addison disease | Malignant hypertension causes bilateral disc edema from hypertensive retinopathy rather than true papilledema (mechanism is different, but appearance overlaps) |
| Dural arteriovenous fistula | High-flow fistula causing venous hypertension | May present identically to IIH; catheter angiography is diagnostic when suspected |
Diagnostic Workup
Systematic Approach
The evaluation of suspected papilledema follows a structured sequence designed to first exclude life-threatening causes, then establish a diagnosis, and finally quantify the degree of visual compromise for monitoring.
Workup Algorithm
- Step 1 — Confirm papilledema: Dilated fundoscopy; distinguish from pseudopapilledema (see below). If uncertain, OCT and B-scan ultrasound help differentiate.
- Step 2 — Brain imaging: MRI brain with gadolinium + MR venography (MRV). This excludes mass lesions, hydrocephalus, CVST, meningeal disease, and dural AV fistula. CT venogram is an alternative if MRI is contraindicated.
- Step 3 — Lumbar puncture: Performed ONLY after imaging excludes a mass lesion with risk of herniation. Measure opening pressure (lateral decubitus position, legs extended); normal ≤25 cm H2O in adults. Collect CSF for cell count, protein, glucose, cytology, and cultures as clinically indicated.
- Step 4 — Baseline visual assessment: Automated visual field testing (Humphrey 24-2 or 30-2), OCT (RNFL thickness), visual acuity, color vision, pupil exam
- Step 5 — Identify etiology: If imaging and CSF are unremarkable and opening pressure is elevated, consider IIH (by modified Dandy criteria). Review medications. Consider additional testing (thrombophilia workup, autoimmune serologies) based on clinical context.
MRI Findings Suggestive of Raised ICP
- Partially empty sella: Elevated CSF pressure compresses the pituitary gland against the sellar floor
- Distension of the perioptic subarachnoid space: Widened fluid signal around the optic nerves, particularly anteriorly
- Flattening of the posterior sclera: The elevated perioptic pressure indents the posterior globe
- Optic nerve head protrusion: The swollen disc protrudes into the vitreous cavity
- Tortuosity of the optic nerves: Vertical tortuous course suggesting chronic elevated perioptic pressure
- Transverse sinus stenosis: Bilateral stenosis is common in IIH; may be a cause or consequence of elevated ICP (debated); some patients benefit from venous sinus stenting
Lumbar Puncture
| Parameter | Normal | Significance |
|---|---|---|
| Opening pressure | ≤25 cm H2O (adults) | >25 cm H2O is elevated; >40 cm H2O is severely elevated; measurement requires lateral decubitus position with legs extended |
| CSF composition | Normal protein, glucose, cells | Must be normal for IIH diagnosis; abnormalities suggest meningitis, carcinomatosis, or sarcoidosis |
| Therapeutic LP | Remove 20–40 mL of CSF | Temporary symptom relief; useful for acute headache management and as a bridge to definitive therapy |
| Sedation/anxiety effect | Can falsely lower OP | Anxious patients or those with Valsalva may have falsely high pressures; ensure relaxed positioning |
Pseudopapilledema
Pseudopapilledema refers to an elevated or blurred optic disc appearance that mimics papilledema but is not caused by elevated ICP. The critical distinction from true papilledema avoids unnecessary and potentially harmful investigations (lumbar puncture). Optic disc drusen (ODD) are the most common cause.
Optic Disc Drusen
- Prevalence: Found in ~1–2% of the general population; bilateral in 75% of cases; familial predisposition
- Pathology: Calcified, laminated acellular deposits within the optic nerve head, anterior to the lamina cribrosa; they elevate the disc surface and obscure disc margins
- Appearance: Elevated disc with irregular, lumpy margins; may show a scalloped border; vessels are not obscured (they curve over the elevated surface rather than being buried by edema); absent spontaneous venous pulsations (not specific)
- Visual field defects: Slowly progressive arcuate defects or nasal steps due to chronic compression of nerve fibers by the drusen; visual field loss occurs in 25–70% of patients with ODD
| Feature | True Papilledema | Pseudopapilledema (ODD) |
|---|---|---|
| Disc margin | Blurred, elevated, edematous halo extending into peripapillary retina | Irregular, lumpy, scalloped; drusen may be visible as refractile bodies |
| Vessels | May be obscured by edematous tissue; vessel tortuosity and congestion common | Vessels curve over the elevated surface but are NOT obscured; absence of venous congestion |
| Hemorrhages | Peripapillary splinter/flame hemorrhages (especially grades 3–5) | Rare (occasional peripapillary hemorrhage from drusen-related vessel compression) |
| Spontaneous venous pulsations | Absent (elevated ICP impedes venous return); however, 20% of normals also lack SVP | May be present or absent (not reliable for differentiation) |
| OCT RNFL | Diffusely thickened (edema); improves with treatment of ICP | May be thickened (drusen elevate measurements) but with characteristic "lumpy" profile; RNFL may thin over time from drusen-related axonal loss |
| B-scan ultrasound | Elevated disc without calcification; may show distended optic nerve sheath (>5.5 mm diameter) | Bright, hyperechoic deposits within the disc (calcified drusen); highly sensitive and specific |
| Fundus autofluorescence | No autofluorescence of disc | Drusen autofluoresce brightly — highly specific finding |
| Enhanced depth imaging (EDI) OCT | Thickened RNFL from edema; no subretinal hyporeflective masses | Hyporeflective round structures within the disc substance (buried drusen); this is the most sensitive modality for detecting buried ODD |
Other Causes of Pseudopapilledema
- Tilted disc: Congenital disc anomaly with oblique insertion of the optic nerve; nasal disc margin appears elevated while temporal margin is recessed; associated with inferonasal visual field defect from retinal thinning (not nerve fiber layer loss)
- Myelinated retinal nerve fibers: White, feathery appearance extending from the disc into the retina; does not represent true edema
- Hyperopic disc: Small, crowded disc in hyperopic eyes may appear elevated; refraction helps clarify
- Bergmeister papilla: Embryonic remnant of the hyaloid artery on the disc surface
When Pseudopapilledema May Coexist with True Papilledema
- Patients with optic disc drusen can also develop true papilledema from a separate cause of elevated ICP
- New headaches, transient visual obscurations, or CN6 palsy in a patient with known ODD should prompt re-evaluation including neuroimaging and possible LP
- Serial OCT comparison and B-scan ultrasound can help identify superimposed edema in patients with pre-existing drusen
- Do not assume that all disc elevation in a patient with known drusen is from drusen alone
Idiopathic Intracranial Hypertension (IIH)
Modified Dandy Criteria
Diagnostic Criteria for IIH
- 1. Signs and symptoms of raised intracranial pressure (headache, papilledema, visual symptoms, CN6 palsy)
- 2. No localizing neurologic signs except CN6 palsy
- 3. Normal brain parenchyma on neuroimaging (no mass, hydrocephalus, or structural abnormality); MRV shows no venous sinus thrombosis
- 4. Elevated opening pressure on lumbar puncture: >25 cm H2O in adults; >28 cm H2O in children (if not sedated and not obese)
- 5. Normal CSF composition (protein, glucose, cell count within normal limits)
- 6. No other identifiable cause of intracranial hypertension (medications, systemic conditions)
Note: "IIH without papilledema" (IIHWOP) is recognized — elevated ICP with headache and other symptoms but without disc edema. This diagnosis requires caution and exclusion of other headache disorders.
Treatment of IIH
| Intervention | Details | Evidence |
|---|---|---|
| Weight loss | Target 5–10% body weight reduction; most effective long-term strategy | Prospective studies show significant ICP reduction and papilledema improvement with modest weight loss; bariatric surgery for refractory cases |
| Acetazolamide | First-line medical therapy; starting dose 500 mg BID, titrate up to 2–4 g/day as tolerated | IIHTT (Wall et al., JAMA 2014): acetazolamide + diet superior to placebo + diet for visual field improvement at 6 months; NNT = 5 for visual field improvement |
| Topiramate | Alternative to acetazolamide; 50–200 mg/day; has carbonic anhydrase inhibitor properties + appetite suppression | Small RCT showed comparable efficacy to acetazolamide; useful when weight loss is a priority or acetazolamide is not tolerated |
| Serial lumbar puncture | Temporary measure; remove 20–40 mL CSF; provides acute symptom relief | Bridge therapy for acute symptoms or while awaiting surgical intervention; CSF reaccumulates within hours |
| Optic nerve sheath fenestration (ONSF) | Surgical decompression of the perioptic subarachnoid space; primarily for vision-threatening papilledema | Effective for stabilizing/improving vision; may not relieve headache; risk of failure/re-closure over time |
| CSF diversion (VP/LP shunt) | Ventriculoperitoneal or lumboperitoneal shunt for refractory cases | Effective for both headache and papilledema; high revision rate (50% at 2 years); shunt failure is common |
| Venous sinus stenting | Endovascular stenting of stenosed transverse sinuses; emerging approach | Response rates of 80–90% in selected patients with significant venous sinus stenosis and pressure gradient ≥8 mmHg across the stenosis; long-term data still accumulating |
Fulminant IIH
Emergency Management: Vision-Threatening Papilledema
- Fulminant IIH: Rapidly progressive papilledema with rapid visual decline (days to weeks rather than months); occurs in a minority of IIH patients but constitutes a neuro-ophthalmic emergency
- Presentation: Severe, high-grade papilledema (Frisen 4–5) with rapidly progressive visual field loss, decreasing acuity, and/or severely constricted fields on presentation
- Immediate steps: High-dose IV acetazolamide (500 mg IV then 250 mg q6h) or IV methylprednisolone (for temporizing only); serial therapeutic lumbar punctures to lower ICP while awaiting definitive intervention
- Surgical intervention: Optic nerve sheath fenestration or CSF shunting should be pursued urgently (within days) when medical therapy is insufficient to protect vision
- Monitoring frequency: Visual fields and OCT should be repeated every 1–2 weeks in the acute phase until stable
- Key principle: Do NOT rely on visual acuity alone — visual fields are far more sensitive for detecting deterioration. A patient with 20/20 acuity can have severely constricted fields and be at risk for permanent blindness.
Monitoring Papilledema
Visual Field Testing
- Humphrey visual field (HVF) 24-2 or 30-2: The standard for monitoring visual function in papilledema; performed at baseline and at regular intervals (monthly initially, then every 3–6 months once stable)
- Mean deviation (MD): The most commonly used summary measure; worsening MD indicates progressive visual field loss
- Typical field loss pattern: Enlarged blind spot (earliest) → inferonasal constriction → generalized constriction → central scotoma (late)
- IIHTT primary outcome: Perimetric mean deviation was the primary endpoint in the landmark IIH Treatment Trial
OCT in Papilledema
OCT Monitoring Pearls
- Acute papilledema: RNFL is markedly thickened (edema); values may exceed 200–400 μm in severe cases (normal ~90–100 μm)
- Improving papilledema: RNFL thickness decreases toward normal with successful ICP reduction; serial measurements track treatment response
- Chronic atrophy: RNFL eventually thins BELOW normal (<75 μm), indicating irreversible axonal loss despite resolution of edema
- GCIPL: Ganglion cell-inner plexiform layer thinning is a more specific marker of neuronal loss (not confounded by edema) and can detect damage even when RNFL is artificially elevated by swelling
- Practical tip: In active papilledema, RNFL thickness tracks edema severity; GCIPL thinning tracks irreversible damage. Both should be monitored together.
- Caution: RNFL measurements are unreliable when disc edema is severe (signal attenuation, segmentation errors); interpret with clinical context
Papilledema in Special Populations
Children
- IIH in children is less strongly associated with obesity, especially in prepubertal children
- Opening pressure thresholds are higher in children: >28 cm H2O (non-sedated, non-obese); >25 cm H2O under sedation
- Secondary causes (venous sinus thrombosis, medications, infections) are more common in children than in adults and must be thoroughly excluded
- Visual prognosis is generally good with treatment; however, children may not report visual symptoms until significant loss has occurred
Pregnancy
- IIH may present or worsen during pregnancy due to weight gain
- Acetazolamide is pregnancy category C; use is controversial but may be justified if vision is threatened
- Serial LPs can be used as a temporizing measure
- ONSF or shunting is reserved for vision-threatening cases refractory to medical management
- Delivery planning: vaginal delivery is safe in most cases; epidural anesthesia is preferred (avoids CSF leak from spinal)
Prognosis
- IIH: With appropriate treatment, most patients maintain useful vision. Visual field loss at presentation is the strongest predictor of final visual outcome. Approximately 25% of patients have permanent visual field deficits despite treatment.
- Fulminant IIH: Without emergent intervention, can cause permanent severe bilateral visual loss or blindness within days to weeks
- Secondary papilledema: Prognosis depends on the underlying cause; CVST-related papilledema generally improves with anticoagulation; tumor-related papilledema depends on tumor management
- Long-term recurrence: IIH recurrence rates of 8–37% have been reported, often associated with weight regain; long-term weight management is essential
Board-Relevant Clinical Pearls
- Papilledema is bilateral by definition; unilateral disc edema in the setting of raised ICP can occur but should prompt consideration of other diagnoses (optic neuritis, ischemic optic neuropathy, infiltrative process)
- Foster Kennedy syndrome: Optic atrophy in one eye (from prior compression by a mass) with contralateral papilledema (from raised ICP); classically caused by olfactory groove meningioma. Pseudo-Foster Kennedy: sequential NAION causing atrophy in one eye and acute disc edema in the other
- CN6 palsy in raised ICP is a false localizing sign: It reflects the vulnerability of the long intracranial course of CN6, not a focal brainstem lesion
- IIHTT key result: Acetazolamide (mean dose ~2.5 g/day) + low-sodium weight loss diet significantly improved visual fields compared with placebo + diet at 6 months
- Absent spontaneous venous pulsations: Suggestive but not diagnostic of elevated ICP; 20% of normal individuals lack visible SVPs; conversely, the PRESENCE of SVPs effectively excludes elevated ICP (>95% NPV)
- MRV is non-negotiable: CVST can perfectly mimic IIH and is a treatable cause of raised ICP; every patient with new papilledema needs venous imaging
- Medication review: Always ask about tetracyclines (minocycline for acne is a classic scenario in young women), vitamin A supplements, retinoids (isotretinoin), and recent corticosteroid withdrawal
References
- Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). JAMA. 2014;311(16):1641-1651.
- Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159-1165.
- Hayreh SS. Pathogenesis of optic disc edema in raised intracranial pressure. Prog Retin Eye Res. 2016;50:108-144.
- Chen JJ, Bhatti MT. Papilledema. Continuum (Minneap Minn). 2024;30(4):1091-1117.
- Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088-1100.
- Frisén L. Swelling of the optic nerve head: a staging scheme. J Neurol Neurosurg Psychiatry. 1982;45(1):13-18.
- Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2012;83(5):488-494.
- Agarwal A, Vibha D, Srivastava AK, et al. Cerebral venous sinus thrombosis presenting as pseudotumor cerebri syndrome: a systematic review and meta-analysis. J Neurol. 2021;268(5):1743-1753.
- Paton L, Holmes G. The pathology of papilloedema: a histological study of sixty eyes. Brain. 1911;33(4):389-432.
- Saber H, Lewis W, Goenka A, et al. Venous sinus stenting for idiopathic intracranial hypertension: a systematic review and meta-analysis. J Neurointerv Surg. 2018;10(7):621-627.
- Fraser JA, Bruce BB, Rucker J, et al. Risk factors for idiopathic intracranial hypertension in men: a case-control study. J Neurol Sci. 2010;290(1-2):86-89.
- Optic Disc Drusen Studies Consortium. Optic disc drusen: diagnosis, monitoring, and treatment — recommendations by the European Optic Disc Drusen Studies Group. Eur J Ophthalmol. 2023;33(1):144-159.
- Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ. 2010;341:c2701.
- Smith SV, Friedman DI. The idiopathic intracranial hypertension treatment trial: a review of the outcomes. Headache. 2017;57(8):1303-1310.